Literature DB >> 31798714

Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate-induced ulcerative colitis in mice.

Zhaoyang Liu1, Wenbo Xie2, Mingru Li2, Jing Liu1, Xiao Liang1, Tao Li3.   

Abstract

Polaprezinc (PZ), a chelate of zinc and L-carnosine, has been widely used in the treatment of gastric ulcers since 1994. In recent years, researchers have found PZ to have a beneficial effect on various experimentally induced models of colitis in mice. In the present study, 6% dextran sodium sulfate (DSS) was used to induce a model of ulcerative colitis (UC) in Institute of Cancer Research mice. The therapeutic effect and mechanism of PZ action in a model of UC was studied in order to provide an experimental basis for the clinical application of PZ in UC treatment. The effect of PZ on UC was evaluated in five groups of mice: A vehicle control only group, a DSS model control group (DSS, 6%), a validated treatment control group (DSS 6% + Mesalamine), a low-dose PZ treatment group (DSS 6% + PZ 60 mg/kg) and a high-dose PZ group (DSS 6% + PZ 120 mg/kg). After the animals were sacrificed, blood was collected and the serum levels of NF-κB and tumor necrosis factor-α (TNF-α) were measured. Changes in histology were observed by light microscopy. The protein levels of AKT, phosphorylated AKT and heat shock protein 70 (HSP70) were determined by western blot analysis. The results suggested that PZ reduced the DSS-induced increase in the inflammatory proteins TNF-α and NF-κB in the UC model. The high-dose of PZ also increased the HSP70 protein level, inhibited AKT phosphorylation in a DSS-induced UC animal model, and decreased white blood cell and neutrophil % counts compared to levels in an untreated DSS control group. Histopathology indicated that the mice of the DSS model group had irregular colonic villi, a large number of inflammatory cells and mucosal damage, whereas mice of the group treated with PZ had small intestinal villus morphology and their villi showed signs of recovery from the damage of UC. The results of the present study indicated that PZ significantly alleviates DSS-induced UC in mice, relieves diarrhea, and inhibits the phosphorylation of inflammatory factors and the inflammatory AKT signaling pathway.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  NF-κB; dextran sodium sulfate; heat shock protein 70; mesalamine; polaprezinc; serine/threonine-specific protein kinase AKT phosphorylation; tumor necrosis factor-α; ulcerative colitis

Year:  2019        PMID: 31798714      PMCID: PMC6878896          DOI: 10.3892/etm.2019.8155

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  37 in total

1.  Polaprezinc attenuates cyclophosphamide-induced cystitis and related bladder pain in mice.

Authors:  Masahiro Murakami-Nakayama; Maho Tsubota; Saki Hiruma; Fumiko Sekiguchi; Kenji Matsuyama; Takeshi Kimura; Masahiro Moriyama; Atsufumi Kawabata
Journal:  J Pharmacol Sci       Date:  2015-01-28       Impact factor: 3.337

2.  Ginger extract and polaprezinc exert gastroprotective actions by anti-oxidant and growth factor modulating effects in rats.

Authors:  Joshua K Ko; Catherine C Leung
Journal:  J Gastroenterol Hepatol       Date:  2010-12       Impact factor: 4.029

3.  Tissue processing and hematoxylin and eosin staining.

Authors:  Ada T Feldman; Delia Wolfe
Journal:  Methods Mol Biol       Date:  2014

Review 4.  Applicability of zinc complex of L-carnosine for medical use.

Authors:  T Matsukura; H Tanaka
Journal:  Biochemistry (Mosc)       Date:  2000-07       Impact factor: 2.487

5.  Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis.

Authors:  Munenori Itagaki; Masayuki Saruta; Hiroki Saijo; Jimi Mitobe; Seiji Arihiro; Mika Matsuoka; Tomohiro Kato; Masahiro Ikegami; Hisao Tajiri
Journal:  Scand J Gastroenterol       Date:  2013-11-29       Impact factor: 2.423

6.  Dextran sulfate sodium (DSS)-induced colitis in mice.

Authors:  Benoit Chassaing; Jesse D Aitken; Madhu Malleshappa; Matam Vijay-Kumar
Journal:  Curr Protoc Immunol       Date:  2014-02-04

Review 7.  Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets.

Authors:  Fiorella Biasi; Gabriella Leonarduzzi; Patricia I Oteiza; Giuseppe Poli
Journal:  Antioxid Redox Signal       Date:  2013-03-01       Impact factor: 8.401

8.  Oral treatment of pressure ulcers with polaprezinc (zinc L-carnosine complex): 8-week open-label trial.

Authors:  Kensaku Sakae; Hiroyuki Yanagisawa
Journal:  Biol Trace Elem Res       Date:  2014-04-03       Impact factor: 3.738

Review 9.  Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.

Authors:  Lilliana Oliveira; Russell D Cohen
Journal:  Drug Des Devel Ther       Date:  2011-02-27       Impact factor: 4.162

Review 10.  Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?

Authors:  Fabiana Andréa Moura; Kívia Queiroz de Andrade; Juliana Célia Farias Dos Santos; Orlando Roberto Pimentel Araújo; Marília Oliveira Fonseca Goulart
Journal:  Redox Biol       Date:  2015-10-23       Impact factor: 11.799

View more
  1 in total

1.  Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment.

Authors:  Silvane Maria Fonseca Murta; Laila Alves Nahum; Jéssica Hickson; Lucas Felipe Almeida Athayde; Thainá Godinho Miranda; Policarpo Ademar Sales Junior; Anderson Coqueiro Dos Santos; Lúcia Maria da Cunha Galvão; Antônia Cláudia Jácome da Câmara; Daniella Castanheira Bartholomeu; Rita de Cássia Moreira de Souza
Journal:  Parasit Vectors       Date:  2022-06-06       Impact factor: 4.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.